LipidRescue® is an investigational drug; the safety and efficacy of the drug have not been approved or authorized by FDA. LipidRescue® is a proposed proprietary name that is subject to FDA approval.
The medical literature suggests that LipidRescue® has contributed to saving countless lives. Dozens of published peer-reviewed reports support its potential efficacy and safety in treating LAST and potentially contributing to survival from various types of NODO.
Dr. Guy Weinberg discovered that LipidRescue® Therapy (infusing a lipid emulsion) rapidly reverses severe LAST in rats and dogs.
The journal Anesthesiology published the first case report of LipidRescue® Therapy saving a patient with LAST.
Annals of Emergency Medicine published the first report of LipidRescue® Therapy in non-opiate drug overdose.
Advisories published by the American Society of Regional Anesthesia and Pain Medicine and the Association of Anesthetists of Great Britain and Ireland established LipidRescue® Therapy as first-line treatment for LAST.
The American Heart Association recommended LipidRescue® Therapy in LAST and other, specific types of drug overdose including certain types of NODO.
ResQ Pharma received Orphan Drug designation from the FDA for use of LipidRescue® Therapy in the treatment of LAST. ResQ anticipates filing an NDA for a kit to treat LAST in 2022
LipidRescue® is an investigational drug; the safety and efficacy of the drug have not been approved or authorized by FDA.
LipidRescue® is a proposed proprietary name that is subject to FDA approval.
Website designed by JDW
Copyright © 2021 ResQ Pharma, Inc - All Rights Reserved.
Powered by GoDaddy